ALZN - Company ID 0001677077
The table below shows Alzamend Neuro, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $710.69K | $3.95M | $376.05K | $5.14M | $14.06M | $1.93M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.76M |
| $4.18M |
| $455.24K |
| $5.84M |
| $14.41M |
| $2.91M |
| Property, plant & equipment | $314.87K | $425.61K | $176.35K | $79.84K | $102.91K | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $2.08M | $4.60M | $631.59K | $5.92M | $14.52M | $2.91M |
| Accounts payable | - | - | $2.93M | $2.87M | $1.16M | $503.59K |
| Total current liabilities | - | - | - | $2.87M | $1.16M | $899.64K |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $1.35M | $634.76K | $3.23M | $2.87M | $1.16M | - |
| Retained earnings | -$67.31M | -$58.54M | -$54.02M | -$44.07M | -$29.19M | -$16.83M |
| Total equity | $733.21K | $3.97M | -$2.59M | $3.05M | $13.35M | $2.01M |